As shown in Fig. 3f, the marked increase of PMP induced by PAR-4 agonist was entirely abolished by ALLN, underlying the calpain pivotal role in releasing PMP in T2DM with poor glycemic control. Here, F2RL3 is linked to type 2 diabetes mellitus.